Nodal lesions with SAD >10 mm and <15 mm are non- measurable. The sum of the diameters (LD for extranodal target lesions, SAD for nodal lesions) is followed through the course of therapy Not differentiated from other tumor measurements •Based on Wolchok et al., 2009 Page 82 Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Derivation of irRC Overall Responses * (Modified for RECIST 1.1. Criteria) Measurable response Non-measureable response Overall response Index and new, measurable lesions (tumor burden)** % Non-index lesions New, non- measurable lesions Using irRC ↓ 100 Absent Absent irCR/\ ↓ 100 Stable Any irPR/\ ↓ 100 Unequivocal progression Any irPR/\ ↓ ≥ 30 Absent/ Stable Any irPR/\ ↓ ≥ 30 Unequivocal progression Any irPR/\ ↓ <30 to <20↑ Absent/ Stable Any irSD ↓ <30 to <20↑ Unequivocal progression Any irSD ≥ 20↑ Any Any irPD/\ * Based on Wolchok et al., 2009 **Decreases assessed relative to baseline, including measurable lesions only (>5 x 5 mm). /\Assuming response (irCR or irPR) and progression (irPD) are confirmed by a second consecutive assessment at least 4 weeks apart. Defining immune -related Response Criteria by RECIST 1.1 criteria at the appropriate radiographic assessment time points (irDCR at the second consecutive radiographic assessment ): 1. Any patient with stable disease or progressive disease at any time in the trial with "rapid clinical deterioration" felt to be related to disease progression is irPD 2. Any patient who meets the criteria for RECIST 1.1 CR at a radiographic assessment time point is irCR 3. Any patient who meets the criteria for RECIST 1.1 PR at a rad iographic assessment time point is irPR 4. Any patient who meets the criteria for RECIST 1.1 SD at a radiographic assessment time point is irSD 5. A patient with RECIST 1.1 PD but no rapid clinical deterioration may stay on study if his/her next tumor measurement evaluation is stable disease or better. 6. If patient has first time PD by RECIST 1.1 criteria, call it unconfirmed PD for irRC RECIST 1.1. 7. A patient with unconfirmed irPD at a radiographic assessment time point whose next tumor measurement is S D or better will be considered to be included in the irDCR at the second consecutive radiographic assessment time point. 8. A patient with unconfirmed irPD at a radiographic assessment time point who fails to qualify for RECIST 1.1 SD or unconfirmed CR or PR by next tumor measurement will be considered to have RECIST 1.1 PD and irPD at the initial radiographic assessment time point. Page 83 Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 APPENDIX C AL IMTA Prescribing Information Page 84 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALIMTA safely and effectively. See full prescribing information for ALIMTA. ALIMTA (pemetrexed for injection) Lyophilized Powder, for Solution for Intravenous Use Initial U.S. Approval: 2004 --------------------------- RECENT MAJOR CHANGES -------------------------- Warnings and Precautions, Third Space Fluid (5.7) --- removal 11/2011 ---------------------------- INDICATIONS AND USAGE --------------------------- ALIMTA®is a folate analog metabolic inhibitor indicated for: • Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: • Initial treatment in combination with cisplatin. (1.1) • Maintenance treatment of patients whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.